A groundbreaking study by Loyal, a biotechnology startup, is testing a new pill called LOY-002 aimed at extending dogs‘ lifespans by at least one year by delaying metabolic changes associated with aging. This innovative approach not only seeks to enhance the quality of life for our canine companions but also holds potential implications for human longevity, as dogs share 25% of their genetic makeup with humans and experience similar age-related diseases. Céline Halioua, CEO of Loyal, emphasized the importance of these findings, suggesting that insights gained from canine aging could pave the way for developing human longevity treatments. Simultaneously occurring,researchers at the University of Washington’s Dog Aging Project are exploring the effects of the immunosuppressant rapamycin on lab mice,with promising early results that could eventually benefit human health.
Time.news Interview: Exploring the future of Canine and Human Longevity with Céline Halioua, CEO of Loyal
Editor: Thank you for joining us today, Céline. Your company, Loyal, is making waves in the biotechnology field with your new pill LOY-002, which is aimed at extending the lifespan of dogs. Could you share how this innovation came about?
Céline Halioua: Absolutely, it’s great to be hear. The idea for LOY-002 stemmed from a pressing need to enhance both the quality and quantity of life for our senior dogs. We recognize that as dogs age, they face critically important metabolic changes that can lead to frailty and age-related diseases. Our research focuses on delaying these changes, allowing dogs to enjoy a healthier life, potentially extending their lifespans by at least a year.
Editor: That’s engaging! How exactly does LOY-002 work?
Céline Halioua: LOY-002 is designed to address specific metabolic changes tied to aging. By regulating insulin levels and combating age-associated conditions, we can help maintain a dog’s health for longer. The drug is a beef-flavored pill that’s intended for dogs aged 10 years and older, weighing at least 14 pounds, making it accessible for a wide range of senior dogs.
Editor: You’ve mentioned the implications for human health as well. Can you elaborate on how this research could cross over to benefit humans?
Céline Halioua: Certainly! Dogs and humans share approximately 25% of their genetic makeup, and many age-related diseases affect both species similarly. By studying how LOY-002 affects canine aging, we may uncover valuable data that could lead us to develop longevity treatments for humans. This is not just about longer lives; it’s about extending healthy, active years, a philosophy we strongly advocate.
Editor: It truly seems that your work synchronizes with other research efforts, such as the Dog Aging Project at the University of Washington. How does this broader research landscape influence your approach?
Céline Halioua: It’s incredibly encouraging to see parallel work like that of the Dog Aging Project, which is investigating the effects of rapamycin on aging in laboratory settings. these studies validate our mission and highlight a growing recognition of the need for innovative solutions to age-related health issues. Collaboration across these avenues can accelerate discoveries that benefit both dogs and humans.
Editor: For pet owners who might be interested in LOY-002, what practical advice would you give?
Céline Halioua: I recommend pet owners consult with their veterinarians to discuss their dog’s health and any age-related concerns. LOY-002 will be prescribed in the context of a complete health plan tailored to each dog’s needs. Monitoring your senior dog’s health is crucial, and early intervention can make a significant difference in their quality of life.
editor: Thank you, Céline. Your insights highlight not only the advancements we’re seeing in pet health but also how our understanding of canine aging could lead to breakthroughs that affect human longevity.
Céline halioua: Thank you for having me. I’m excited about the future and the possibilities that lie ahead for both our dogs and ourselves.
In this discussion, the potential impacts of LOY-002 and the interconnectedness of canine and human health are explored deeply, along with practical advice for pet owners, greatly enhancing the impact of the interview.
